Evidence map›Paper›PMID 41362362›Full record

ArticleInternational journal of nanomedicine2025

Local M1 Macrophage Reprogramming with Gluconic Acid-Coated Selenium Nanoparticles.

Zi-Xian Liao, Da-Liang Ou, Chia-Lang Hsu, Lin-Ni Lu, Cheng-Han Wen, Lin Lu, Chun-Lun Chiu, Pan-Chyr Yang, S-Ja Tseng

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zi-Xian LiaoInstitute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung, Taiwan.ORCID 0000-0002-3051-0728
Da-Liang OuGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.ORCID 0000-0002-8368-1141
Chia-Lang HsuGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.ORCID 0000-0002-7447-8045
Lin-Ni LuInstitute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung, Taiwan.
Cheng-Han WenDepartment of Research and Development, True Diamond Health Co., Ltd, Taoyuan, Taiwan.
Lin LuDepartment of Research and Development, True Diamond Health Co., Ltd, Taoyuan, Taiwan.ORCID 0000-0003-4074-9625
Chun-Lun ChiuDepartment of Research and Development, True Diamond Health Co., Ltd, Taoyuan, Taiwan.
Pan-Chyr YangDepartment of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
S-Ja TsengDepartment of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.ORCID 0000-0002-1299-7202

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: While reprogramming tumor-associated macrophages (TAMs) using cytokines shows promise for cancer therapy, its clinical translation is limited by poor bioavailability. Essential mineral selenium (Se), via selenoproteins, is crucial for innate immunity and adaptive immunity regulation. Methods: Addressing the need for safer, more effective methods to enhance macrophage function, we leveraged the essential mineral Se to create gluconic acid-coated Se nanoparticles (GA-SeNPs). The in vivo efficacy of GA-SeNPs was assessed via intratumoral injection in a B16-F10 melanoma BALB/c mouse model, mirroring the administration route of the first virotherapy for advanced melanoma. Results: These nanoparticles successfully induced M2-to-M1 macrophage repolarization and inhibited cancer cell growth through reactive oxygen species (ROS) generation. We confirmed through transcriptomic analysis that GA-SeNPs influence the genes of key components in the biosynthesis of selenoproteins. Additionally, GA-SeNPs influence oxidative phosphorylation, inflammatory, and ribosome pathways by promoting the shift of M2 macrophages to an M1 phenotype. Crucially, in a melanoma mouse model, GA-SeNPs treatment yielded a >4-fold tumor weight reduction and effectively repolarized TAMs to an M1 phenotype while maintaining TAMs levels. GA-SeNPs inhibit cancer growth in vivo by disrupting the immunosuppressive tumor microenvironment. They maintain total TAM counts while strongly promoting M2-to-M1 repolarization. Conclusion: Their dual localization within both TAMs and cancer cells further highlights their therapeutic potential, presenting a promising strategy to advance TAM-based cancer therapies and improve clinical outcomes.

Indexed as

GluconatesMacrophagesMelanoma, ExperimentalNanoparticlesSeleniumTumor-Associated MacrophagesAnimalsCell Line, TumorCellular ReprogrammingHumansMiceMice, Inbred BALB CReactive Oxygen SpeciesTumor MicroenvironmentGluconatesgluconic acidReactive Oxygen SpeciesSeleniumapoptosisreactive oxygen speciesrepolarizationselenium nanoparticlestumor-associated macrophages

Identifiers

PMID41362362
PMCPMC12682305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.